Trial Profile

A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Serabelisib (Primary)
Indications Adenocarcinoma; Clear cell sarcoma; Colon cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Rectal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Faeth Therapeutics

06 Oct 2025 Status changed from active, no longer recruiting to completed.
27 Feb 2025 Planned End Date changed from 1 Sep 2024 to 1 Dec 2025.
27 Feb 2025 Planned primary completion date changed from 1 Sep 2024 to 1 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com